AbbVie Inc. : A likely recovery
Entry price | Target | Stop-loss | Potential |
---|
$57.05 |
$0 |
$54.1 |
-100% |
---|
Technical indicators currently tested are likely to allow AbbVie shares to rally again.
The research-based biopharmaceutical company displays high-quality fundamentals. It has an attractive valuation with a P/E ratio of 13.3x for 2015 and an appealing yield of 3.43%. Reuters estimates shows its outstanding growth potential and its rising profitability: EPS should increase by 290% in 2015.
Technically, the stock is in an oversold situation. Prices came back on their lower ascendant trendline on both daily and weekly data. The stock seem to start a technical rebound at this level. Thus, the stock could find new energy and rise towards the next USD 61.7 resistance.
Therefore, it seems opportune to take a long position on AbbVie and target in a first place the USD 61.7 resistance. Traders should not insist below the USD 55.5 support and a stop-loss order should be placed under this threshold.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.